Hospitals in California are facing critical decisions on patient care; the FDA and CDC are investigating a multistate hepatitis A outbreak; 6 pharmaceutical giants are being investigated for their potential roles in the opioid crisis.
With the wildfires ravaging California this year, and the state facing intermittent power outages, hospitals, clinics, and patients have been facing a greater number of decisions where critical care is concerned, according to California Healthline. Disaster plans may cover temporary power outages—all California hospitals need to have back-up generators on site with enough diesel fuel to run for 72 hours—but officials still need to make the difficult choice between critical care situations and services they can postpone. With no end to the shortages in site, hospitals and clinics may need to come up with alternate backup plans.
With 14 cases so far in Indiana, Michigan, Minnesota, Nebraska, and Wisconsin, the most recent being reported on November 15, the FDA and CDC have traced the origins of a multistate outbreak of hepatitis A to berries from an 11-state distribution center for Fresh Thyme Farmers Market stores, according to the FDA. For berries purchased September 9-30 but not consumed, the FDA says to throw them out. And for anyone who consumed them in the previous 2 weeks and is not vaccinated against hepatitis A, they may need postexposure prophylaxis. Also, those who think they may have been sickened by the berries should consult their physician.
Pending investigation by federal prosecutors from the US Attorney’s office in the Eastern District of New York, criminal charges could be filed against 4 pharmaceutical companies and 2 distributors for their possible roles in the ongoing opioid crisis, says Reuters. Under the Controlled Substances Act (CSA), companies must report unusually large or frequent orders of opioids, and these subpoenas are part of a probe into violations of the act, according to filings. In 2016, Cardinal Health was fined $44 million for violating the CSA, and in July, Miami-Luken Inc, an Ohio distributor was charged after it shipped millions of opioid pills to Appalachia.
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Gene and Cell Therapies Hold Potential—but How Can Payers Manage Their Costs?
April 18th 2024Presenters at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting discussed the current promise and future potential of gene and cell therapies, as well as payer management strategies for these costly treatments.
Read More
Survival Rates in CLL: Targeted Agents vs Fludarabine Combo Therapy Study
April 17th 2024Researchers conducted an analysis of 4 phase 3 trials, covering 2751 patients, to address the potential for targeted agents in younger and physically fit patients who have chronic lymphocytic leukemia (CLL).
Read More